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Abstract 
Introduction: Transplant is the replacement with therapeutic purposes, of organs, tissues or cellular material for 
others, from a donor who is usually a human, alive or dead. In recent years, transplant organs have been developed 
by the advances that have occurred with immunosuppressive drugs and medical-surgical technology. Due to the 
frequency of transplants that are performed today, it is common to find these patients in dental clinics. 
Objectives: To review the literature on oral manifestations in transplant patients and general dental management 
and according to transplant organs (heart, lung, liver, kidney, pancreas and bone marrow). 
Material and Methods: For the literature review, we carried out a search in Pubmed / Medline database using limits 
and keywords according to the controlled vocabulary “Medical Subject Headings” (MeSH). We obtained a total of 
30 articles (eight literature reviews, three randomized clinical trials, one cohort study, three case-control studies, 
eight clinical case series and seven cross-sectional studies). 
Results and discussion: We describe the most common oral manifestations in transplant patients (viral, bacterial 
and fungal infections, gingival enlargement secondary to drug therapy and higher risk in the development of oral 
malignancy) and the special dental management that should be carried out on these patients, generally and specifi-
cally according to the type of transplant.
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Introduction
We recognize as transplant the replacement, for thera-
peutic purposes, of organs, tissue or cellular material, 
other from a donor who is usually a human being, alive 
or dead. Transplant organs have been developed in re-
cent years thanks to advances that have occurred with 
immunosuppressive drugs and medical-surgical techno-
logy (1,2). Due to the frequency of transplants that are 
performed actually, it is common to find these patients in 
dental clinics, therefore the dentist must understand the 
special dental management that should be carried out on 
these patients.
Transplants have been classified in different ways, one 
of them is by source: autograft or autologous, is deri-
ved from the individual’s own (skin and bone marrow); 
syngeneic or isograft, donors and recipients are identi-
cal twins or homozygous; allograft or allogeneic donors 
and recipients are of the same species but genetically 
different; xenogeneic or xenograft, donors are from di-
fferent species, and finally, from the umbilical cord.
Before a transplant has been performed you have to 
evaluate the immune status of the recipient to prevent 
rejection of the graft. Figure 1 summarizes the immune 
components involved in the mechanism of immune re-
Figure 1. Helper T cells are activated to recognize antigen presented by the APCs. The activation releases cyotoki-
nes that are mediators of different mechanisms of rejection.  
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patients are submitted to there may be oral impact and 
clinical manifestations can appear that we should consi-
der (1,4,5).
Objectives
The aim of this article was to perform a literature review 
about: 
Oral manifestations in transplant patients. 1. 
General dental management: before and after trans-2. 
plants. 
Special dental management according to transplant 3. 
organs: heart, lung, liver, kidney, pancreas and bone 
marrow.
jection. Depending on the intensity, graft rejection can 
be: hyperacute, acute (Figure 2) or chronic. For the im-
munological study, the following tests have been perfor-
med: ABO blood group of the donor and recipient, HLA 
type determination of the donor and recipient, humoral 
sensitization to HLA antigens and a cross matching test 
(3).
Transplant patients are treated with immunosuppressive 
drugs for the rest of their lives. The drugs most used are: 
cyclosporine, azathioprine and tacrolimus commonly 
associated with glucocorticoids (prednisone). The aim 
of the use of these drugs is to prevent acute rejection, 
to allow the acceptance of the transplanted organ and to 
preserve the patient’s immunity with the least possible 
alteration. Due to immunosuppressive therapy that these 
Figure 2. Immunological mechanism of acute rejection.
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Materials and method
For the literature review, we carried out a literature 
search in Pubmed / Medline database using the following 
words according to the controlled vocabulary (MeSH): 
“dental management”, “oral manifestations”, “trans-
plant patients”, “cardiac transplant”, “lung trans-
plant”, “heart-lung transplant”, “liver transplant”, 
“renal transplant”, “kidney transplant”, “pancreas 
transplant”, “hematopoietic stem cell transplant”.  The 
limits used for the search were:  articles in english or 
spanish and articles published within the last 15 years. 
We reviewed a total of 30 articles (eight literature re-
views, three randomized clinical trials, one cohort study, 
three case-control studies, eight clinical case series and 
seven cross-sectional studies).
Results
Oral manifestations in transplant patients
As a result of the long term immunosuppressive therapy 
that these patients are submitted to, their immune res-
ponse is reduced, which it makes them more suscepti-
ble to develop infections; fungal infection has the hig-
hest degree of mortality rate despite its lower incidence 
compared to bacterial and viral infections. There is an 
increased prevalence of oral candidiasis and the cause 
is usually the species Candida albicans, although an 
increased prevalence of infections caused by other spe-
cies (Candida krusei, Candida tropicalis and Candida 
glabrata) has been observed. Cytomegalovirus infection 
(CMV) is common in the first months after transplant. 
The herpes simplex virus and varicella-Zoster have also 
been observed in these patients. In addition, prolonged 
immunosuppression makes them more vulnerable to hu-
man herpesvirus-8. Several studies refer to the discovery 
of hairy leukoplakia lesions in these groups of patients, 
which is associated with Epstein-Barr virus (1,5-18).  
Another side effect of the use of cyclosporine is gingival 
hyperplasia. It usually affects the facial surfaces of the 
interdental papilla and it may appear on gingival mar-
gins and lingual surfaces. It interferes with the patient’s 
oral hygiene leading to an increased susceptibility to in-
fections, caries and periodontal disease (5,7-11,19).
It has been shown that after transplant there is an in-
creased risk of malignant oral lesions. A greater pre-
disposition to epithelial dysplasia and carcinoma of the 
lip has been observed. There have been several cases 
of squamous cell carcinoma and Kaposi’s sarcoma in 
areas of gingival hyperplasia induced by treatment with 
cyclosporine. In addition, several studies such as Díaz-
Ortiz et al. (2) relate xerostomia after the transplant 
(1,5,7,9,13).
General dental management in transplant patients
Before performing any transplant we must consider ge-
neral dental management (Table 1):
A consultation with the physician is recommended to • 
discuss overall condition of the patient (1-5).
We must educate, inform and motivate the patient to • 
maintain a proper oral hygiene and to be aware of the 
risk and problems that may arise in the oral cavity af-
ter transplant. We must give oral hygiene instructions 
and recommend the use of fluorinated compounds 
and antiseptic mouthwashes such as chlorhexidine 
(1,2,5,19-21).
Dental status should be evaluated. For dental treatment • 
planning, we must carry out a radiographic study. The 
main objectives of dental treatment are (1,2,5,21):
-To maintain adequate periodontal health. We must 
remove supra- and subgingival plaque with den-
tal scaling and curettage.
- Filling of teeth with caries with favorable prog-
nosis.
- Endodontic treatments. 
- Implant treatment must be postponed until the sta-
ble period of the transplant and when the patient’s 
condition has improved. If it is possible to carry 
out implant treatment before transplant, we must 
perform this with sufficient time to evaluate the 
biological response of the abutments teeth or the 
osseointegration of the implants. 
- Extraction of teeth with poor prognosis or uncer-
tain prognosis, periodontally compromised teeth 
with deeper pockets than 5-6 mm, teeth with fur-
cation involvement or endoperiodontal lesions, 
teeth with periapical lesions and teeth with a root 
canal are technically difficult or with uncertain 
prognosis and teeth with  very deep or extensive 
caries.
The therapeutic approaches for the control of gingi-• 
val hyperplasia in patients receiving cyclosporine are 
(2,4,10,22):
- Various authors, such as Ciavarella et al. (10) have 
shown that reducing the dose of cyclosporine or 
substituting it with another immunosuppressant 
such tacrolimus, rifampicin or mycophenolate 
mofetil improves gingival hyperplasia. However, 
the nature of the transplanted organ does not often 
allow the replacement or reduction of the dose. In 
this case, the treatment is based on the prevention 
and elimination of predisposing factors. 
- It had been demonstrated that oral hygiene can 
reduce the degree of gingival hyperplasia by re-
ducing the inflammatory component which has 
produced the plaque but does not inhibit their de-
velopment.
- The need for surgical treatment should be carefu-
lly considered as it is carried out for cosmetic and 
aesthetic reasons. 
Patients who have been treated with corticosteroids • 
for a long time or in stressful situations may require 
supplementation of corticosteroids to prevent adrenal 
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crisis (Table 2 and 3). We also recommend morning 
appointments, a quiet working environment and to 
avoid sudden and unexpected movements during den-
tal treatment (1,9,13). 
We must be careful with the use of certain drugs • 
(1,5):
- General anesthesia.
- Nonsteroidal anti-inflammatory drugs (NSAIDs): 
these drugs enhance the nephrotoxicity of cyclos-
porine and tacrolimus and may increase bleeding 
and exacerbate peptic ulcer disease in patients trea-
ted with corticosteroids. 
- Aspirin increases the risk of bleeding.
- Antibiotics (erythromycin and clarithromycin), 
azole antifungals (ketoconazole, fluconazole and 
itraconazole) and NSAIDs can alter the levels of 
cyclosporine and consequently there is an increase 
in serum levels, rendering patients with a greater 
immnosuppresion than we desire. 
- Co-trimoxazole, tetracyclines, aminoglycosides 
and quinolones increase risk of nephrotoxicity.
After organ transplant has been carried out, we must 
consider several aspects (Table 4); the period of time af-
ter transplant can be divided into: 
General dental management BEFORE transplant
1. A consultation with the physician is recommended to discuss overall condition of the patient.
2. We must give oral hygiene instructions and recommend the use of fluorinated compounds and antiseptic mouthwashes 
such as chlorhexidine.
3. Dental status should be evaluated. For dental treatment planning, we must carry out a radiographic study. The main 
objectives of dental treatment are:
- To maintain adequate periodontal health. We must remove supra- and subgingival plaque with dental scaling and 
curettage.
- Filling of teeth with caries with favorable prognosis.
- Extraction of teeth with poor prognosis or uncertain prognosis, periodontally compromised teeth with deeper pockets 
than 5-6 mm, teeth with furcation involvement or endoperiodontal lesions, teeth with periapical lesions and teeth 
with a root canal are technically difficult or with uncertain prognosis and teeth with very deep or extensive caries.
- Endodontic treatments. 
- Implants treatment must be postponed until the stable period of the transplant and when patient’s condition has im-
proved. 
4. Control of gingival hyperplasia in patients receiving cyclosporine.
5. Patients who have been treated with corticosteroids for a long time or in stressful situations may require supplemen-
tation before dental treatment. 
6. We must be careful with the use of certain drugs (1,5):
- General anesthesia,
- Nonsteroidal anti-inflammatory drugs (NSAIDs),
- Aspirin, 
- Antibiotics (erythromycin, clarithromycin, tetracyclines, aminoglycosides and quinolones), 
- Azole antifungals (ketoconazole, fluconazole and itraconazole),
- Co-trimoxazole.
Table 1. General dental management before transplant.
A CONSERVATIVE dental procedure
Patient’s situation Therapeutic approach
Present corticoid use No supplementing required
Regular corticoid use 
Low-dose corticotherapy (< 
30mg of hydrocortisone/day)
No supplementing required 
High-dose corticotherapy for a 
month if the patient has discon-
tinued use  less than two weeks 
ago
Daily maintenance dose on the day 
of treatment 
High-dose corticotherapy for 
more than a month 
No established regimen
If less than one month with discontinued treatment with corticosteroids No supplementing required 
Table 2. Corticosteroid supplementation with a conservative dental procedure.
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A dental SURGICAL procedure
Patient’s situation Therapeutic approach 
Present corticoid use1. Up to 30 mg / day of hydrocortisone No supplementing required 
More than 40 mg/day of hydrocortisone 
for a month
We must double the daily dose 
on the day of treatment. If 
postoperative pain is expected, we 
should also double the daily dose on 
the first postoperative day.  
30-40 mg/ day of hydrocortisone
Regular corticoid use2. 
Low-dose corticotherapy No supplementing required 
High-dose corticotherapy for a two 
weeks 
High-dose corticotherapy for a month 
if the patient has discontinued use  less 
than two weeks ago
Daily maintenance dose on the day 
of treatment 
High-dose corticotherapy for more than 
a month 
No supplementing required 
Table 3. Corticosteroid supplementation with a dental surgical procedure.
General dental management AFTER transplant
Period of time Dental management
 Immediate (first 1. 
three months after 
surgery)
It is•	  recommended that emergency dental treatment be carried out in a hospital, and that 
specialist be consulted and treated with antibiotic prophylaxis.
The dental treatment will be essentially palliative and local, the aim is to: •	
Prevent hyposalivation and xerostomía: mouthrinses with 0.5% of aqueous - 
solution of sodium carboxy cellulose, every two hours.
Educate the patient about oral higiene: use of very soft toothbrush, fluoride - 
toothpaste and antiseptic mouthrinses such as clorhexidine.
Eliminate risk factors and improve the diet.- 
Remove dentures and orthodontic appliances.- 
Dental examination by the risk of developing malignant lesions.- 
Preventio- n of infections.
Stable 2. 
After•	  three months after transplant, elective dental treatment can be performed. 
Six months after transplant is the best time considered for dental treatment.•	
If invasive dental treatment is necessary, we must give prophylactic antibiotic and •	
a complete blood count is recommended. 
Tra3. nsplant 
rejection: (acute or 
chronic)
Dental t•	 reatment should be postponed.
Only emergency dental treatment should be performed.•	
Prophylact•	 ic treatment with antibiotics may be useful to prevent sepsis.
Table 4. General dental management after transplant.
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1. Immediate (first three months after surgery): this is 
the maximum life-threatening period, so it is recommen-
ded that emergency dental treatment be carried out in 
a hospital, and that specialist be consulted and treated 
with antibiotic prophylaxis. The dental treatment will be 
essentially palliative and local (1,5,9,21), the aim is to: 
- Prevent hyposalivation and xerostomia (mouthrinses 
with 0.5% of aqueous solution of sodium carboxy 
cellulose, every two hours).
- Educate the patient about oral hygiene (use of very 
soft toothbrush, fluoride toothpaste and antiseptic 
mouthrinses such as clorhexidine). 
- Eliminate risk factors (cigarettes and alcohol) and 
improve the diet (soft diet, avoiding irritant, carioge-
nic or excessively hot foods.) 
- Remove dentures and orthodontic appliances.
- Prevention of infections.
2. Stable (more than three months), when no signs of 
rejection have been observed. After three months after 
transplant, elective dental treatment can be performed. 
However, six months after transplant is the best time 
considered for dental treatment. If invasive dental treat-
ment is necessary, we must give prophylactic antibiotic 
and a complete blood count is recommended, because 
the graft anastomosis has not completely epithelialized 
and the patient has a high level of immunosuppression 
(1,5,9,21,23).
3. Transplant rejection: It may be acute or chronic. Acu-
te rejection usually occurs during the first months and 
chronic rejection is often preceded by several episodes of 
acute rejection and usually occurs over a period of years 
(over 5 years). If this occurs, dental treatment should be 
postponed. Only emergency dental treatment should be 
performed. Prophylactic treatment with antibiotics may 
be useful to prevent sepsis (1,21).
Special dental management according to transplanted 
organ
1. Heart transplant
The main causes of end-stage disease are idiopathic car-
diomyopathy and end-stage coronary artery disease. The 
primary indication for heart transplant is end-stage heart 
failure.  This can be the result of ischemic cardiomyopa-
thy with intractable angina (1).
Special dental management for heart transplant pa-•	
tients
- These patients are highly susceptible to hemorrhage 
due to neutropenia, anemia and thrombocytopenia. 
In many cases, patients can be treated with anticoa-
gulants or antiplatelet drugs. We must take special 
care in dental treatment, a complete blood count is 
recommended including the International Normali-
zed Ratio (INR), and apply the appropriate hemos-
tatic measures such as the use of hemostatic agents 
(1). 
- Anesthesia is recommended without vasoconstrictor 
because these patients may be more sensitive to epi-
nephrine (1).
2. Lung transplant
Lung transplant is becoming a recommended treatment 
for patients with nonmalignant end-stage lung disease. 
One of the most common complications is infection. 
Pseudomonas aeruginosa is the most common bacterial 
pathogen, and cytomegalovirus is the most common vi-
ral infection in lung transplant patients (1,24). 
Special dental management for lung transplant pa-•	
tients (1):
- Narcotic analgesics should not be considered becau-
se of their respiratory depression properties. 
- These patients are usually on oxygen therapy. As a 
part of dental management, the use of any combus-
tible products should be avoided. 
3. Heart-lung transplant
Combined heart-lung transplants are performed in cases 
of pulmonary hypertension with right side heart failure 
and Eisenmenger´s syndrome. The other indications are 
multi-organ end-stage disease, congenital abnormalities 
and amyloidosis, and simultaneous end-stage heart and 
lung disease (1,25). 
Special dental management for •	 heart-lung transplant 
patients 
- We will perform the same management as in heart 
and lung transplant for prevention, treatment and 
prophylactic antibiotic therapy. 
- We must control the appearance of malignancies be-
cause of its high risk of incidence (4.6%) (1). 
4. Liver transplant
Liver transplant is an option for treatment of many dif-
ferent disease conditions, though the most common 
indications are chronic liver disorders (biliary and non-
biliary cirrhosis), hepatocellular carcinoma and severe 
acute hepatic failure. In Spain, the most frequent indica-
tion according to the National Transplant Organization 
is cirrhosis secondary to hepatitis C virus (HCV) infec-
tion, followed by alcoholic cirrhosis (1,2,5,23). 
In a study performed by Díaz-Ortiz et al. (2) in liver 
transplant patients (53 patients), the most frequent oral 
manifestations were gingival hyperplasia, xerostomia, 
candidiasis and hairy leukoplakia.
Also, it showed a high prevalence of tongue pathology in 
these patients, particulary fissured tongue, saburral ton-
gue, depapillated tongue, hairy tongue and geographical 
tongue. It should be taken into account that while these 
disorders are generally asymptomatic, they sometimes 
may also present candida overinfection and produce 
symptoms. Other factors such as oral environmental pH 
variations, xerostomia, vitamin A and C and/or calcium 
deficiencies, or some type of anemia have also been im-
plicated (2). 
We must take special care with patients with end-stage 
liver disease as they may frequently experience spon-
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taneous gingival bleeding and we must be careful with 
patients with alcoholic cirrhosis because they often have 
nutritional deficiencies manifesting with the appearance 
of petechiae, ecchymosis, angular cheilitis and glossitis 
with the presence of malignant lesions. It is also com-
mon to find sialadenosis (1).
Special dental management for liver transplant pa-•	
tients
Before liver transplant
- In patients with liver failure who are undergoing li-
ver transplant, we should be especially careful with 
drugs that are metabolized in the liver (1,21):
1. Local anesthetics (lidocaine, prilocaine, mepiva-
caine and bupivacaine) can be used safely when the 
total dose of 7 mg / kg is not exceeded and when 
combined with epinephrine.
2. Analgesics: paracetamol should not be used on a 
chronic basis (no more than two weeks) and must 
not exceed 4g. daily. Ibuprofen and aspirin should 
be avoided because they have a significant hepatic 
metabolism. It is preferable to use morphine as a nar-
cotic analgesic rather than meperidine and codeine, 
because morphine has extra-hepatic metabolism.
3. Antibiotics (clindamycin, metronidazole and van-
comycin): instead of these antibiotics we should use 
beta-lactam antibiotics. 
4. Sedatives (diazepam, lorazepam and midazolam): 
these drugs can be used safely if we reduce the dose 
and if we increase dosing intervals between medi-
cations. 
Although at present, there is no guide for modifying 
dosing intervals of these drugs in transplant patients 
and we should always consult the specialist (1,10).  
- Patients with liver failure often have abnormalities 
of coagulation factors, so there is an increased risk 
of bleeding with any invasive procedure. Before 
treatment, a complete blood count is recommended, 
including platelet count, INR, aspartate aminotrans-
ferase and alanine aminotransferase.  If the platelet 
count is less than 50.000/mm3 the patient should be 
transfused with fresh plasma. After treatment, we 
must take all necessary local hemostatic measures 
(1,21).
After liver transplant
- We must use drugs that are metabolized by the liver 
with caution.
5. Kidney transplant
A kidney transplant is now the treatment of choice for 
patients with end-stage renal disease. The most common 
cause of death in these patients is cardiovascular disease 
and not renal failure, although this is also a complication 
that can occur after transplant (1,6,7,9,11-13,18,26).
Special dental management for kidney•	  transplant pa-
tients 
Before kidney transplant
- We must be careful with the use of some drugs in pa-
tients with end-stage renal disease because as renal 
function is reduced, the plasma levels of some drugs 
may be high or prolonged (1,13).
- Acetaminophen and codeine can be given for posto-
perative pain management (1).
- Local anesthetics are metabolized in the liver and 
hence are safe to use for dental procedures (1).
6. Pancreas transplant
Pancreas transplant can be carried out in conjunction 
with kidney transplant, after kidney transplant, or as a 
pancreas transplant alone. The simultaneous kidney and 
pancreas transplant is the most common type of pan-
creas transplant carried out, representing almost 78% 
of pancreas transplants carried out, and transplant of the 
pancreas alone is generally less than 5% (1,27).
Special dental management for pancreas transplant •	
patients 
Before pancreas transplant
- The patients usually have significant glucose-ma-
nagement problems and hence their glucose levels 
should be considered before treatment. 
7. Hematopoietic cell transplant
Hematopoietic cell transplant serves as a rescue proce-
dure to reconstitute the hematopoietic system when da-
maged by high-dose chemo/radiotherapy for treatment 
of malignancy. Also it is used as an alternative therapy 
for other diseases, especially hematopoietic malignan-
cies such as acute leukemia, multiple myeloma or non-
Hodgkin lymphoma.  2-7 days before hematopoietic cell 
transplant, the patient undergoes a preparative regimen 
consisting of high-dose chemotherapy, irradiation or 
both to accomplish total tumor kill, and to achieve a 
high state of immunosuppression. Then, hematopoietic 
cell transplant is carried out. It consists of infusion of 
donor stem cells through a central venous catheter and 
the patient is kept isolated for 30-60 days to prevent op-
portunistic infections and to evaluate the graft acceptan-
ce (20, 28-30).
The most common oral complications after hematopoie-
tic cell transplant are:
1. Mucositis: it is the most frequent oral complication 
and it occurs by direct action of chemo/radiotherapy on 
mucosal progenitor cells. The World Health Organiza-
tion classifies mucositis in 5 degrees ranging from mild 
erythema to severe mucosal ulcerative breakdown. Se-
vere ulcerations can cause intense pain that interferes 
with eating or drinking. Mucositis becomes clinically 
evident shortly after transplant and peaks five to seven 
days post-transplant and will resolve spontaneously 
approximately 15-22 days after transplant (28,29).
2. Risk of infection (29). 
3. Oral bleeding: it can occur in patients with thrombo-
cytopenia due to acute leukemia or secondary to a mye-
losuppression induced by the chemotherapy (29).
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4. Graft versus host disease (GVHD) is a reaction that 
arises because immunocompetent lymphocytes from 
donor’s bone marrow release cytokines that react against 
recipient’s antigens, which have a different degree of 
histocompatibility of the donor, causing damage in tis-
sues and organs. It is a major cause of morbidity and 
mortality in patients with hematopoietic cell transplant. 
It distinguishes between acute if it occurs in a period less 
than 100 days from the infusion of stem cells and chron-
ic if the period is longer than 100 days. Oral manifesta-
tions of the acute GVHD include xerostomia, mucosal 
lichenoid, papular lesions, erythema, atrophy and ulcer-
ation. Chronic GVHD affects the oral cavity in 80% of 
cases. Oral effects of chronic GVHD include mucosal 
erythema, tongue-surface atrophy, lichenoid changes of 
the buccal mucosa, ulcers and an increased incidence 
of oral cancer in the form of squamous cell carcinoma 
(28,29).
6. Salivary changes and xerostomia: clinical manifesta-
tions include parotitis, increasingly mucinous saliva and 
decreased salivary flow. These features may persist for 
a year after transplant. Full recovery of salivary gland 
function in a two to five month period has been observed 
in patients receiving only chemotherapy or total lym-
phoid irradiation (avoiding parotid glands). Unfortuna-
tely, patients who have received significant radiation to 
their salivary glands or develop GVHD can experience 
chronic persistent of hypofunction of the salivary gland 
(28,29).
Special dental management for hematopoietic cell •	
transplant patients 
Before hematopoietic cell transplant 
- Treatment of mucositis (1,29).
After hematopoietic cell transplant
- To review oral cavity in search of any oral compli-
cation (GVHD) (29).
Discussion
1. The most common oral manifestations in transplant 
patients are: viral, bacterial and fungal infections, gin-
gival hiperplasia due to cyclosporin and higher risk in 
developing oral malignancy.
2. General dental management in transplant patients:
Before transplant: A consultation with the physician is • 
recommended. We must educate the patient to main-
tain a proper oral hygiene. We must be careful with the 
use of certain drugs. Dental status should be evaluated 
and we must carry out a radiographic study.
After transplant: in the first three months after trans-• 
plant, it is recommended that we only carry out emer-
gency dental treatment in a hospital. After three mon-
ths, elective dental treatment can be performed. Six 
months after transplant is the best time considered for 
dental treatment. In case of rejection, only emergency 
dental treatment is recommended. 
3.	Specific	dental	management	in transplant patients:
Heart transplant: • we must use local anesthesia without 
vasoconstrictor.
Lung transplant:•  we must avoid narcotic analgesics.
Heart-lung transplant:•  we must control the appearance 
of malignancies.
Liver transplant:•  We must use drugs that are metaboli-
zed by the liver with caution.
Kidney transplant:•  we must use with caution drugs 
with renal elimination.
Pancreas transplant:•  we must evaluate levels of gluco-
se in the blood.
Hematopoietic cell transplant:•  we must treat mucositis 
and control  GHVD.
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